Renopharm is a leading pharmaceutical company with a proprietary novel technology. Renopharm developed a novel NO donor technology, which shows unique properties:
- Derived form natural sources
- Shows no tolerance activity after repeated administration (Proof of concept on hypertension)
- Outstanding stability and cost efficient manufacturing process

Renopharm uses a unique approach in the synthesis of NO donors; the approach is based on NO attachment to natural chemical groups that are part of physiological compounds or their natural metabolites. This novel form will prevent the formation of drug tolerance by the cells in chronic NO donor treatments and will act synergistically with the vasodilator effect of the released NO to enhance its action.

Dr. Peter Assaf is a chemist who graduated at Marburg University, Germany and who earned his PhD at the Hebrew university in Jerusalem, Israel. Dr. Assaf is the inventor of Renopharm ’s technology and since he founded the firm in 2003 he further developed the NO donor technology and thereof he has derived two lead and 28 other molecules. 

Renopharm team has the mission to further elaborate the entrepreneurial approach of Renopharm, positioning itself as a product orientated company. So far, Renopharm has promising in vivo results to apply its molecules in the field of: 
- Hypertension
- Cardiovascular anti-inflammatory treatment
- Analgesics and other anti-inflammatory applications
- Oncology
- CNS related diseases
- (Coated) medical devices
- Treatment of erectile dysfunction

It was only recently discovered that NO is produced by enzymatic reaction in mammals. Nitric oxide plays an important role in many pathological conditions including: hypertension, diabetes, strokes, intestinal motility, cancer, drug addiction, memory and learning disorders, septic shock, sunburn, anorexia, male impotence and tuberculosis. There are more than 32,000 scientific papers dealing with this remarkable molecule, most of these published within the last five years. Among their other activities, NO donors cause blood vessel expansion (vaso dilatation), allowing the better flow of blood to organs. This action is important in patients suffering from heart failure due to cardio vascular diseases. NO vasodilatation compounds also produce major effects on inflammation and sexual dysfunction.

Under the given opportunities that there are several promising applications to be derived from its technology, all of them under the protection of the filed patents, Renopharm has chosen to pursue its activities under a virtual business model, to work simultaneously with several industrial partners, such an approach will allow Renopharm to fully develop its potential, to leverage investor’s value and to minimize risks.